Cargando…

Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death

Since the earliest findings of Otto Warburg, who discovered the first metabolic differences between lactate production of cancer cells and non-malignant tissues in the 1920s, much time has passed. He explained the increased lactate levels with dysfunctional mitochondria and aerobic glycolysis despit...

Descripción completa

Detalles Bibliográficos
Autores principales: Läsche, Matthias, Emons, Günter, Gründker, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145406/
https://www.ncbi.nlm.nih.gov/pubmed/32300553
http://dx.doi.org/10.3389/fonc.2020.00409
_version_ 1783519994330480640
author Läsche, Matthias
Emons, Günter
Gründker, Carsten
author_facet Läsche, Matthias
Emons, Günter
Gründker, Carsten
author_sort Läsche, Matthias
collection PubMed
description Since the earliest findings of Otto Warburg, who discovered the first metabolic differences between lactate production of cancer cells and non-malignant tissues in the 1920s, much time has passed. He explained the increased lactate levels with dysfunctional mitochondria and aerobic glycolysis despite adequate oxygenation. Meanwhile, we came to know that mitochondria remain instead functional in cancer cells; hence, metabolic drift, rather than being linked to dysfunctional mitochondria, was found to be an active act of direct response of cancer cells to cell proliferation and survival signals. This metabolic drift begins with the use of sugars and the full oxidative phosphorylation via the mitochondrial respiratory chain to form CO(2), and it then leads to the formation of lactic acid via partial oxidation. In addition to oncogene-driven metabolic reprogramming, the oncometabolites themselves alter cell signaling and are responsible for differentiation and metastasis of cancer cells. The aberrant metabolism is now considered a major characteristic of cancer within the past 15 years. However, the proliferating anabolic growth of a tumor and its spread to distal sites of the body is not explainable by altered glucose metabolism alone. Since a tumor consists of malignant cells and its tumor microenvironment, it was important for us to understand the bilateral interactions between the primary tumor and its microenvironment and the processes underlying its successful metastasis. We here describe the main metabolic pathways and their implications in tumor progression and metastasis. We also portray that metabolic flexibility determines the fate of the cancer cell and ultimately the patient. This flexibility must be taken into account when deciding on a therapy, since singular cancer therapies only shift the metabolism to a different alternative path and create resistance to the medication used. As with Otto Warburg in his days, we primarily focused on the metabolism of mitochondria when dealing with this scientific question.
format Online
Article
Text
id pubmed-7145406
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71454062020-04-16 Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death Läsche, Matthias Emons, Günter Gründker, Carsten Front Oncol Oncology Since the earliest findings of Otto Warburg, who discovered the first metabolic differences between lactate production of cancer cells and non-malignant tissues in the 1920s, much time has passed. He explained the increased lactate levels with dysfunctional mitochondria and aerobic glycolysis despite adequate oxygenation. Meanwhile, we came to know that mitochondria remain instead functional in cancer cells; hence, metabolic drift, rather than being linked to dysfunctional mitochondria, was found to be an active act of direct response of cancer cells to cell proliferation and survival signals. This metabolic drift begins with the use of sugars and the full oxidative phosphorylation via the mitochondrial respiratory chain to form CO(2), and it then leads to the formation of lactic acid via partial oxidation. In addition to oncogene-driven metabolic reprogramming, the oncometabolites themselves alter cell signaling and are responsible for differentiation and metastasis of cancer cells. The aberrant metabolism is now considered a major characteristic of cancer within the past 15 years. However, the proliferating anabolic growth of a tumor and its spread to distal sites of the body is not explainable by altered glucose metabolism alone. Since a tumor consists of malignant cells and its tumor microenvironment, it was important for us to understand the bilateral interactions between the primary tumor and its microenvironment and the processes underlying its successful metastasis. We here describe the main metabolic pathways and their implications in tumor progression and metastasis. We also portray that metabolic flexibility determines the fate of the cancer cell and ultimately the patient. This flexibility must be taken into account when deciding on a therapy, since singular cancer therapies only shift the metabolism to a different alternative path and create resistance to the medication used. As with Otto Warburg in his days, we primarily focused on the metabolism of mitochondria when dealing with this scientific question. Frontiers Media S.A. 2020-03-31 /pmc/articles/PMC7145406/ /pubmed/32300553 http://dx.doi.org/10.3389/fonc.2020.00409 Text en Copyright © 2020 Läsche, Emons and Gründker. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Läsche, Matthias
Emons, Günter
Gründker, Carsten
Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
title Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
title_full Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
title_fullStr Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
title_full_unstemmed Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
title_short Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
title_sort shedding new light on cancer metabolism: a metabolic tightrope between life and death
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145406/
https://www.ncbi.nlm.nih.gov/pubmed/32300553
http://dx.doi.org/10.3389/fonc.2020.00409
work_keys_str_mv AT laschematthias sheddingnewlightoncancermetabolismametabolictightropebetweenlifeanddeath
AT emonsgunter sheddingnewlightoncancermetabolismametabolictightropebetweenlifeanddeath
AT grundkercarsten sheddingnewlightoncancermetabolismametabolictightropebetweenlifeanddeath